Posts Tagged: Pfizer Canada

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

MaRS Innovation and Pfizer fund Bio-Manufacturing Technology

Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership. Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area. This announcement was covered by BetaKit. His technology generates cell lines with improved protein production and survival properties, important in the ... Read more

Dr. Raphael Hofstein in Biotechnology Focus: Building a catalytic reaction across Canada’s Life Sciences Sector

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein. The article explores the role of catalysis in building Canada's Life Sciences sector: In chemistry, according to Encyclopædia Britannica Online, a catalyst is any substance that increases a reaction’s rate without itself being consumed. Kinetically, Wikipedia tells us, catalytic reactions are typical chemical reactions where the reaction rate depends on the reactants’ frequency of contact in the rate-determining step. Usually, ... Read more

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013. The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ... Read more

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor Toronto, December 6, 2011 —  The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research. The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…) Read more